犬造血干细胞移植的作用机制及应用研究进展

doi:10.16431/j.cnki.1671-7236.2022.02.042

摘要/Abstract

摘要： 造血干细胞(hematopoietic stem cell, HSC)位于造血系统的顶端, 是造血系统中唯一具有多能性和自我更新能力的细胞, 可以分化为各种功能的血细胞, 维持血液系统的建立和动态平衡, 是目前研究最为透彻、临床应用最为成熟的成体干细胞。造血干细胞的这些重要特性, 使得基于造血干细胞在治病机制研究和临床应用中的研究取得了很大进展。以造血干细胞为基础的再生医学治疗是目前治疗恶性血液病和遗传病的首选方法, 如造血干细胞治疗犬白细胞黏附缺陷综合征、犬遗传性贫血、犬淋巴瘤、犬白细胞减少症、犬X连锁严重联合免疫缺陷病等, 但由于白细胞抗原匹配的供体稀缺、可获得的造血干细胞数量有限等原因, 无法满足临床需求, 因此, 如何通过体外培养获得满足临床需要的造血干细胞成为近年来学者们研究的热点问题。作者参照现有研究成果对造血干细胞的来源和体外分离培养、治病机制进行系统的描述, 并对造血干细胞移植治疗遗传性溶血性贫血、白细胞黏附缺陷综合征、淋巴瘤、白细胞减少症、X连锁严重联合免疫缺陷病的临床研究进行综述, 以期为今后将造血干细胞广泛应用于临床治疗提供参考依据。

关键词: 犬; 造血干细胞; 移植; 体外扩增; 归巢

Abstract: Hematopoietic stem cells (HSCs) are located at the top of the hematopoietic system, they are the only cells that have pluripotency and self-renewal ability in the hematopoietic system.They can differentiate into blood cells with various functions to maintain the establishment and dynamic balance of the blood system, which were the most thoroughly studied adult stem cells with the most mature clinical application.These important characteristics of hematopoietic stem cells have made great progress in the study of disease treatment mechanisms and clinical applications based on hematopoietic stem cells.Regenerative medicine treatment based on hematopoietic stem cells is currently the first choice for the treatment of hematological malignancies and genetic diseases, such as treatment of canine leukocyte adhesion defect syndrome, canine hereditary anemia, canine lymphoma, canine leukopenia, canine X-linked severe combined immunodeficiency using HSCs, etc., but due to the scarcity of leukocyte antigen-matched donors and the limited number of available hematopoietic stem cells, it cannot meet clinical needs.Therefore, how to obtain hematopoietic stem cells to meet clinical needs through in vitro culture has become a hot issue for scholars in recent years.With reference to existing research results, the authors systematically described the sources, in vitro isolation and culture, and treatment mechanism of hematopoietic stem cells, and summarized the clinical research of hematopoietic stem cell transplantation in the treatment of hereditary hemolytic anemia, leukocyte adhesion deficiency syndrome, lymphoma, leukopenia and X-linked severe combined immunodeficiency disease, in order to provide references for the wide application of hematopoietic stem cells in clinical treatment in the future.

Key words: dog; hematopoietic stem cells; transplantation; in vitro expansion; homing

中图分类号:

田仰清, 汪娅媛, 昂艳芬, 严涵, 刘鑫, 严玉霖. 犬造血干细胞移植的作用机制及应用研究进展[J]. 中国畜牧兽医, 2022, 49(2): 791-799.

TIAN Yangqing, WANG Yayuan, ANG Yanfen, YAN Han, LIU Xin, YAN Yulin. Research Progress on Therapeutic Mechanism and Application of Canine Hematopoietic Stem Cell Transplantation[J]. China Animal Husbandry and Veterinary Medicine, 2022, 49(2): 791-799.

参考文献

[1] BECKER A, MCCULLOCH E, TILL J. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells[J]. Nature, 1963, 197(11): 452-454.
[2] SIMINOVITCH L, MCCULLOCH E, TILL J. The distribution of colony-forming cells among spleen colonies[J]. Journal of Cellular and Comparative Physiology, 1963, 62(3): 327-336.
[3] WU A, TILL J, SIMINOVITCH L, et al. Cytological evidence for a relationship between normal hemotopoietic colony-forming cells and cells of the lymphoid system[J]. Journal of Experimental Medicine, 1968, 127(3): 455-464.
[4] EAVES C J. Hematopoietic stem cells: Concepts, definitions, and the new reality[J]. Blood, 2015, 125(17): 2605-2613.
[5] SHEN Y H, OTEIZA A, CAO H, et al. Analyzing hematopoietic stem cell homing, lodgment, and engraftment to better understand the bone marrow niche[J]. Annals of the New York Academy of Sciences, 2014, 1310(1): 119-128.
[6] CHANDER V, GANGENAHALLI G. Emerging strategies for enhancing the homing of hematopoietic stem cells to the bone marrow after transplantation—Science Direct[J]. Experimental Cell Research, 2020, 390(1): 111954.
[7] 张庆云, 董芳. 体外产生可移植的人造血干细胞的研究进展[J]. 中国实验血液学杂志, 2020, 28(1): 320-324.
ZHANG Q Y, DONG F. Research advance on in vitro generation of human hematopoietic stem cells for transplantation[J]. Journal of Experimental Hematology, 2020, 28(1): 320-324. (in Chinese)
[8] GAO X, XU C, ASADA N, et al. The hematopoietic stem cell niche: From embryo to adult[J]. Development, 2018, 145(2): 139691-139697.
[9] CHENG H, ZHENG Z, CHENG T. New paradigms on hematopoietic stem cell differentiation[J]. Protein Cell, 2019, 11(1): 34-44.
[10] HOFER T, RODEWALD H R, et al. Differentiation-based model of hematopoietic stem cell functions and lineage pathways[J]. Blood, 2018, 132(11): 1106-1113.
[11] 魏伟, 许超, 叶志勇, 等. 混合培养体系中间充质干细胞与造血干细胞生物学特性[J]. 生理学报, 2016, 68(5): 691-698.
WEI W, XU C, YE Z Y, et al. Biological characteristics of mesenchymal stem cell and hematopoietic stem cell in the co-culture system[J]. Acta Physiologica Sinica, 2016, 68(5): 691-698. (in Chinese)
[12] 袁雅红, 李东升, 周春芳. 间充质干细胞条件培养基和细胞因子联合应用扩增造血干细胞[J]. 湖北医药学院学报, 2020, 39(5): 35-38.
YUAN Y H, LI D S, ZHOU C F. Combined application of mesenchymal stem cell conditioned medium and cytokines to expand hematopoietic stem cells[J]. Journal of Hubei University of Medicine, 2020, 39(5): 35-38. (in Chinese)
[13] 葛俊男. 脐带血造血干细胞的分离与贮藏工艺过程研究[D]. 石家庄: 河北科技大学, 2019.
GE J N. Study on the separation and storage process of cord blood hematopoietic stem cells[D]. Shijiazhuang: Hebei University of Science and Technology, 2019. (in Chinese)
[14] 马逸群, 邵丽诗, 万珊杉, 等. 大鼠骨髓间充质干细胞分离方法的改良与比较[J]. 广东医学, 2020, 41(14): 1417-1420.
MA Y Q, SHAO L S, WAN S S, et al. Improvement and comparison of existing methods for isolating bone mesenchymal stem cells of rats[J]. Guangdong Medical Journal, 2020, 41(14): 1417-1420. (in Chinese)
[15] 汪姝玥, 林凡莉, 钱怡, 等. 不同共培养模式下间充质干细胞对造血干细胞增殖的作用[J]. 中国组织工程研究, 2018, 22(13): 2068-2074.
WANG S Y, LIN F L, QIAN Y, et al. Coculture with mesenchymal stem cells facilitates the proliferation of hematopoietic stem cells under different coculture modes[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(13): 2068-2074. (in Chinese)
[16] SONG K, FAN X, LIU T, et al. Simultaneous expansion and harvest of hematopoietic stem cells and mesenchymal stem cells derived from umbilical cord blood[J]. Journal of Materials Science, 2010, 21(12): 3183-3193.
[17] KADEKAR D, KALE V, LIMAYE L. Differential ability of MSCs isolated from placenta and cord as feeders for supporting ex vivo expansion of umbilical cord blood derived CD34⁺ cells[J]. Stem Cell Research & Therapy, 2015, 6(1): 201.
[18] GLENN J D, WHARTENBY K A. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy[J]. World Journal of Stem Cells, 2014, 6(5): 526-539.
[19] LIU G Y, LIU Y, LU Y, et al. Short-term memory of danger signals or environmental stimuli in mesenchymal stem cells: Implications for therapeutic potential[J]. Cellular & Molecular Immunology, 2016, 13(3): 369-378.
[20] 郭娟, 张迪, 李龙, 等. 细胞自噬对犬骨髓间充质干细胞干性的影响[J]. 畜牧兽医学报, 2020, 51(2): 166-174.
GUO J, ZHANG D, LI L, et al. Effect of autophagy on the stemness of canine bone marrow mesenchymal stem cells[J]. Acta Veterinaria et Zootechnica Sinica, 2020, 51(2): 166-174. (in Chinese)
[21] KO K H, NORDON R, O'BRIEN T A, et al. Ex vivo expansion of haematopoietic stem cells to improve engraftment in stem cell transplantation[J]. Methods in Molecular Biology, 2017, 1534: 301-311.
[22] 刘亚军, 丁如愿, 杨刚, 等. 原花青素对人牙髓干细胞的增殖及成骨分化作用的研究[J]. 安徽医科大学学报, 2021, 56(11): 1728-1733.
LIU Y J, DING R Y, YANG G, et al. Effects of proanthocyanidins on the proliferation and osteogenic differentiation of human dental pulp stem cells[J]. Acta Universitatis Medicinalis Anhui, 2021, 56(11): 1728-1733. (in Chinese)
[23] NALDINI L. Genetic engineering of hematopoiesis: Current stage of clinical translation and future perspectives[J]. EMBO Molecular Medicine, 2019, 11(3): e9958-e9970.
[24] 曾梦颖, 闫晓霞, 刘欢欢, 等. 犬干细胞技术的研究进展及临床应用[J]. 上海畜牧兽医通讯, 2016, 4: 16-18.
ZENG M Y, YAN X X, LIU H H, et al. Research progress and clinical application of canine stem cell technology[J]. Shanghai Journal of Animal Husbandry and Veterinary Medicine, 2016, 4: 16-18. (in Chinese)
[25] ZHANG Q S. Stem cell therapy for fanconi anemia[J]. Biology and Engineering, 2018, 1083: 19-28.
[26] 孟强. 提高脐血造血干细胞移植归巢的研究进展[J]. 国际检验医学杂志, 2011, 32(3): 366-368.
MENG Q. Research progress on improving the homing of cord blood hematopoietic stem cell transplantation[J]. International Journal of Laboratory Medicine, 2011, 32(3): 366-368. (in Chinese)
[27] XU D, YANG M, CAPITANO M, et al. Pharmacological activation of nitric oxide signaling promotes human hematopoietic stem cell homing and engraftment[J]. Leukemia, 2021, 35(1): 229-234.
[28] YIN Y, LI X, HE X T, et al. Leveraging stem cell homing for therapeutic regeneration[J]. Journal of Dental Research, 2017, 96(6): 601-609.
[29] LIESVELD J L, SHARMA N, ALJITAWI O S. Stem cell homing: From physiology to therapeutics[J]. Stem Cells, 2020, 38(10): 1241-1253.
[30] CHEN L X, LI Y H, CHEN W C, et al. Enhanced recruitment and hematopoietic reconstitution of bone marrow marrow-derived mesenchymal stem cells in bone marrow failure by the SDF/CXCR4[J]. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14(9): 1250-1260.
[31] AJAMI M, SOLEIMANI M, ABROUN S, et al. Comparison of cord blood CD34⁺ stem cell expansion in coculture with mesenchymal stem cells overexpressing SDF-1 and soluble/membrane isoforms of SCF[J]. Journal of Cellular Biochemistry, 2019, 120(9): 15297-15309.
[32] BIANCHIM E, MEZZAPELLE R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration[J]. Frontiers in Immunology, 2020, 11: 2109-2117.
[33] ZHOU Y, CAO H B, LI W J, et al. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy[J]. Chinese Journal of Natural Medicines, 2018, 16(11): 801-810.
[34] PERLIN J R, SPORRIJ A, ZON L I. Blood on the tracks: Hematopoietic stem cell-endothelial cell interactions in homing and engraftment[J]. Journal of Molecular Medicine, 2017, 95(8): 809-819.
[35] CHEN C C, CHEN R F, WANG Y C, et al. Combination of a CD26 inhibitor, G-CSF, and short-term immunosuppressants modulates allotransplant survival and immunoregulation in a rodent hindlimb allotransplant model[J]. Transplantation, 2020, 105(6): 1250-1260.
[36] WANG Y Q, LAI S P, TANG J, et al. Prostaglandin E₂ promotes human CD34⁺ cells homing through EP2 and EP4 in vitro[J]. Molecular Medicine Reports, 2017, 16(1): 639-646.
[37] XU J, CHEN Y, LIU Y, et al. Effect of SDF-1/Cxcr4 signaling antagonist AMD3100 on bone mineralization in distraction osteogenesis[J]. Calcified Tissue International, 2017, 100(6): 641-652.
[38] SCHOEDEL, KRISTINA, MORCOS, et al. The bulk of the hematopoietic stem cell population is dispensable for murine steady-state and stress hematopoiesis[J]. Experimental Hematology, 2016, 44(9): S97.
[39] LIU F, XIA J, ZHANG Y, et al. Hematopoietic hierarchy——An updated roadmap[J]. Trends in Cell Biology, 2018, 28(12): 976-986.
[40] FRANK J T, STAAL, et al. The functional relationship between hematopoietic stem cells and developing T lymphocytes[J]. Annals of the New York Academy of Sciences, 2016, 1370(1): 36-44.
[41] SEET C S, HE C, BETHUNE M T, et al. Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids[J]. Nature Methods, 2017, 14(5): 521-530.
[42] MELCHERS F. Checkpoints that control B cell development[J]. Journal of Clinical Investigation, 2015, 125(6): 2203-2210.
[43] 朱剑, 林冬静. 造血干细胞研究进展[J]. 吉林医药学院学报, 2013, 34(3): 218-221.
ZHU J, LIN D J. Progress in research of hematopoietic stem cell[J]. Journal of Jilin Medical University, 2013, 34(3): 218-221. (in Chinese)
[44] SATISH K, NANDAKUMAR, JACOB C, et al. Advances in understanding erythropoiesis: Evolving perspectives[J]. British Journal of Haematology, 2016, 173(2): 206-218.
[45] BARMINKO J, REINHOLT B, BARON M H. Development and differentiation of the erythroid lineage in mammals[J]. Developmental & Comparative Immunology, 2016, 58: 18-29.
[46] NISHIKⅡ H, KURITA N, CHIBA S. The road map for megakaryopoietic lineage from hematopoietic stem/progenitor cells[J]. Stem Cells Translational Medicine, 2017, 6(8): 1661-1665.
[47] UPADHAYA S, SAWAI C M, PAPALEXI E, et al. Kinetics of adult hematopoietic stem cell differentiation in vivo[J]. Journal of Experimental Medicine, 2018, 215(11): 2815-2832.
[48] 张无瑕, 王芬, 何杨, 等. 丙酮酸激酶缺乏症1例及文献复习[J]. 现代医药卫生, 2020, 36(18): 2997-2999.
ZHANG W X, WANG F, HE Y, et al. A case of pyruvate kinase deficiency and literature review[J]. Journal of Modern Medicine & Health, 2020, 36(18): 2997-2999. (in Chinese)
[49] GRACE R F, BARCELLINI W. Management of pyruvate kinase deficiency in children and adults—Science Direct[J]. Blood, 2020, 136(11): 1241-1249.
[50] 魏春梅. 一例吉娃娃犬的丙酮酸激酶缺乏性贫血的诊疗[J]. 山东畜牧兽医, 2015, 36(4): 36.
WEI C M. Diagnosis and treatment of a case of pyruvate kinase deficiency anemia in Chihuahuas[J]. Shandong Journal of Animal Science and Veterinary Medicine, 2015, 36(4): 36. (in Chinese)
[51] WEIDEN P, STORB R, GRAHAM T, et al. Severe hereditary haemolytic anaemica in dogs treated by marrow trasplantation[J]. British Journal of Haematology, 2010, 33(3): 357-362.
[52] TROBRIDGE G D, BEARD B, WU R A, et al. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency[J]. PLoS One, 2012, 7(9): e45173.
[53] SHIMOMURA M, DOI T, NISHIMURA S, et al. Successful allogeneic bone marrow transplantation using immunosuppressive conditioning regimen for a patient with red blood cell transfusion dependent pyruvate kinase deficiency anemia[J]. Hematology Reports, 2020, 12(1): 8305-8308.
[54] TEWARI N, MATHUR V P, YADAV V S, et al. Leukocyte adhesion defect-Ⅰ: Rare primary immune deficiency[J]. Special Care in Dentistry, 2017, 37(6): 309-313.
[55] HORIKOSH I, YASU O, UMED A, et al. Allogeneic hematopoietic stem cell transplantation for leukocyte adhesion deficiency[J]. Journal of Pediatric Hematology Oncology, 2018, 40(2): 137-140.
[56] BAUER T R, TUSCHONG L M, CALVO K R, et al. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency[J]. Molecular Therapy, 2013, 21(5): 964-972.
[57] ROSE D D, GILIANI S, NOTARANGELO L D, et al. Long term outcome of eight patients with type 1 leukocyte adhesion deficiency (lad-1): Not only infections, but high risk of autoimmune complications[J]. Clinical Immunology, 2018, 191: 75-80.
[58] GRüNTZIG K, GRAF R, HSSIG M, et al. The Swiss canine cancer registry: A retrospective study on the occurrence of tumours in dogs in Switzerland from 1955 to 2008[J]. Journal of Comparative Pathology, 2015, 152(2-3): 161-171.
[59] 周芸, 林德贵. 犬淋巴瘤概述[A]. 中国畜牧兽医学会小动物医学分会. 第六届西部宠物医师大会论文集[C]. 2017.
ZHOU Y, LIN D G. Overview of canine lymphoma[A]. Small Animal Medicine Branch of Chinese Society of Animal Husbandry and Veterinary Medicine. Proceedings of the Sixth Western Conference of Pet Physicians[C]. 2017. (in Chinese)
[60] RICHARDS K L, SUTER S E. Man' s best friend: What can pet dogs teach us about non-Hodgkin's lymphoma?[J]. Immunological Reviews, 2015, 263(1): 173-191.
[61] SHIMOKAWA MIYAMA T, UMEKI S, BABA K, et al. Neutropenia associated with osteomyelitis due to hepatozoon canis infection in a dog[J]. Journal of Veterinary Medical Science, 2011, 73(10): 1389-1393.
[62] 毛红瑞. 犬白细胞减少症的病因与治疗[J]. 浙江畜牧兽医, 2010, 35(2): 35-36.
MAO H R. Causes and treatment of canine leukopenia[J]. Zhejiang Journal Animal Science and Veterinary Medicine, 2010, 35(2): 35-36. (in Chinese)
[63] SCHNELLE A, BARGER A. Neutropenia in dogs and cats: Causes and consequences[J]. Veterinary Clinics of North America Small Animal Practice, 2012, 42(1): 111-122.
[64] 汪登如, 曹景锋, 谢丽君, 等. 犬骨髓干细胞对犬白细胞减少症的治疗效果观察[J]. 中国兽医杂志, 2016, 52(9): 77-78.
WANG D R, CAO J F, XIE L J, et al. Observation on the therapeutic effect of canine bone marrow stem cells on canine leukopenia[J]. Chinese Journal of Veterinary Medicine, 2016, 52(9): 77-78. (in Chinese)
[65] FELSBURG P J, RAVIN S D, MALECH H L, et al. Gene therapy studies in a canine model of X-linked severe combined immunodeficiency[J]. Human Gene Therapy Clinical Development, 2015, 26(1): 50-56.
[66] HASSAN A, LEE P, MAGGINA P, et al. Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency[J]. Journal of Allergy and Clinical Immunology, 2014, 133(6): 1660-1666.
[67] HEIMALL J, PUCK J, BUCKLEY R, et al. Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation (HCT) for severe combined immunodeficiency patients: A consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT[J]. Biology of Blood and Marrow Transplantation, 2017, 23(3): 379-387.
[68] CHAN W Y, ROBERTS R L, MOORE T B, et al. Cord blood transplants for SCID: Better B-cell engraftment?[J]. Journal of Pediatric Hematology Oncology, 2013, 35(1): E14-E18.
[69] MAGANTI H B, BAILEY ADRIAN J M, KIRKHAM A M, et al. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies[J]. Stem Cells Translational Medicine, 2021, 10(7): 996-1007.
[70] XU L, WANG J, LIU Y, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia[J]. New England Journal of Medicine, 2019, 381(13): 1240-1247.
[71] PAVANI G, FABIANO A, LAURENT M, et al. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells[J]. Blood Advances, 2021, 5(5): 1137-1153.